Literature DB >> 18391999

Can 'double blockbuster' strengthen Amgen's backbone?

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18391999     DOI： 10.1038/nbt0408-361

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Amgen/UCB build on bone franchise with anti-sclerostin antibody.

Authors:  Suzanne Elvidge
Journal:  Nat Biotechnol       Date:  2016-06-09       Impact factor: 54.908

Review 2.  Cathepsin K inhibitors for osteoporosis and potential off-target effects.

Authors:  Dieter Brömme; Fabien Lecaille
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.